Andrew G. Reaume

DOI:10.5912/jcb1011


Abstract:

For the last 15 years the drug discovery strategy referred to as “drug-repositioning” has been a recognized approach towards bringing new therapeutics to market and has continued to grow in popularity over this time frame.  Melior Discovery is a company with a founding mission centered on drug repositioning.  The author shares his perspective on lessons learned over 15 years of conducting drug repositioning efforts, complete with advantages and disadvantages that he has encountered using this approach and why, overall, this means of drug discovery provides a compelling business rationale.